Signals
39Tobacco use disorder pharmacotherapy widens past nicotine replacement and varenicline
Cytisine availability, novel nicotine receptor pharmacotherapy, and integrated behavioural-and-pharmacological care delivery are reshaping tobacco use disorder management.
Insomnia comorbid with mental health conditions acquires structured therapy options
Daridorexant maturity, cognitive-behavioural therapy for insomnia (CBT-I) digital expansion, and integrated mental-health-and-insomnia treatment models are reshaping comorbid insomnia care.
Hemophilia gene therapy real-world data starts to clarify durability
Approved factor VIII and factor IX gene therapy products are accumulating real-world durability data that defines the addressable-population reality.
OCD and intractable-condition options widen
Deep brain stimulation, transcranial magnetic stimulation, and emerging psychedelic-assisted therapy are all reaching into refractory OCD.
Fertility therapy moves from procedural to pharmacological
Pharmacological adjuncts and oocyte-quality interventions are expanding the fertility-therapy toolset beyond the IVF procedural footprint.
Tardive dyskinesia therapy access patterns
Approved VMAT2 inhibitor therapy for tardive dyskinesia continues to expand but underdiagnosis remains the primary gap.
PAH combination therapy moves to first-line
Pulmonary arterial hypertension upfront combination therapy is becoming standard rather than sequential single-agent escalation.
FDA approves leucovorin calcium as first treatment for CFD-FOLR1
The FDA has approved expanded use of Wellcovorin (leucovorin calcium) tablets for cerebral folate deficiency caused by confirmed FOLR1 gene variants, marking the first approved treatment for this rare neurological condition in adults and children.
FDA approves tividenofusp alfa for neurologic Hunter syndrome
The FDA approved Avlayah (tividenofusp alfa-eknm) to treat the neurologic manifestations of MPS II (Hunter syndrome), marking the first therapy specifically indicated for the CNS dimension of this rare lysosomal storage disorder.
FDA approves first gene therapy for severe LAD-I
The FDA approved Kresladi (marnetegragene autotemcel), the first gene therapy indicated for severe Leukocyte Adhesion Deficiency Type I, marking the first approved treatment specifically targeting the genetic root cause of this rare, life-threatening immune disorder.
NICE's rejection of lecanemab and donanemab is widening the transatlantic access gap
Final NICE guidance declined both anti-amyloid antibodies for routine NHS use on cost-effectiveness grounds. The same products are reimbursed in Germany and approved (with payer fragmentation) in the US. The bifurcation is hardening rather than resolving.
Donanemab's limited-duration treatment paradigm is reshaping the lifetime cost calculation against lecanemab
Donanemab's protocol stops dosing once amyloid clearance is achieved, typically 12-18 months. Lecanemab is continuous indefinitely. Over a 10-year treatment horizon, the implied lifetime cost difference is substantial.
Plasma biomarker testing is displacing amyloid PET as the screening modality for anti-amyloid eligibility
Three FDA-cleared blood tests for amyloid pathology are now in routine use at major Alzheimer's centres, materially reducing the amyloid-PET demand that constrained early lecanemab uptake.
ARIA monitoring infrastructure is the rate-limit on anti-amyloid uptake
Centres prescribing lecanemab and donanemab consistently report that MRI surveillance capacity, not patient demand or insurance approval, is the bottleneck on how many patients they can treat in 2026.
Adult ADHD prescribing patterns are being reshaped by stimulant supply normalisation
The acute stimulant supply shortages that characterised 2022 to 2024 in adult ADHD are normalising. Prescribing patterns are stabilising at higher absolute levels than pre-shortage, with implications for both the established stimulant class and the non-stimulant pipeline.
Glaucoma drug-delivery implant uptake reveals the procedure-room workflow constraint
Sustained-release glaucoma drug-delivery implants are addressing the chronic adherence problem that has characterised glaucoma management for decades. Real-world uptake reveals the procedure-room workflow as the principal access constraint.
Long-acting injectable antipsychotic uptake reveals adherence-versus-access gap in schizophrenia
Real-world uptake of long-acting injectable (LAI) antipsychotics in schizophrenia is well below the eligible-population estimate across major markets, despite strong adherence and outcome benefits. The drivers are access infrastructure, prescriber inertia, and patient-pathway operational complexity.
Hypertension treatment intensification gap remains the underdeveloped commercial opportunity
Real-world hypertension control rates across major markets remain substantially below guideline targets, with the treatment-intensification gap (patients on suboptimal regimens not advanced to combination or specialist therapy) as the principal driver. The commercial opportunity in closing this gap is large and is being addressed by combination-therapy programs and by emerging novel mechanisms.
Postpartum depression novel mechanism uptake reveals the maternal-mental-health access gap
The approval of zuranolone for postpartum depression introduced a rapid-acting oral mechanism into a previously underserved indication. Real-world uptake patterns reveal the structural access gap in maternal mental health, with material implications for the commercial trajectory of adjacent maternal mental health pipeline.
Sickle cell disease curative therapy uptake exposes the conditioning-regimen access gap
Approved curative therapies for sickle cell disease (lentiviral gene therapy and CRISPR-edited autologous stem-cell therapy) are facing real-world uptake constrained by the conditioning regimen requirements and the specialist-centre infrastructure for autologous cell therapy.
Geographic atrophy therapy uptake reveals the disease-monitoring infrastructure gap
Real-world uptake of complement C3 and C5 inhibitors for geographic atrophy has been slower and more variable than the pivotal trial benefit profile would have predicted. The drivers are disease-monitoring infrastructure, intravitreal-injection capacity, and the patient-and-clinician decision frame around a slowly progressive condition.
COPD triple-therapy uptake remains uneven across markets
Single-inhaler triple therapy in COPD is the guideline-supported regimen for the eligible population, but real-world uptake remains uneven across major markets driven by step-therapy protocols, prescriber inertia, and access geography.
GLP-1 supply normalisation is shifting the prescribing decision back to clinical fit
Manufacturing capacity for the GLP-1 class has substantially normalised after two years of supply constraint. The prescribing decision is moving back from availability-driven to clinical-fit-driven, and the commercial dynamics are shifting accordingly.
Finerenone CKD uptake reveals the cardio-renal-metabolic prescribing gap
Real-world finerenone uptake in chronic kidney disease patients with type 2 diabetes has been slower than the pivotal trial benefit profile would predict. The drivers are specialist coordination across cardiology, nephrology and endocrinology, and the operational complexity of integrating finerenone into existing regimens.
Friedreich's ataxia real-world treatment uptake reveals the access-versus-efficacy gap
Real-world uptake of the first approved disease-modifying therapy for Friedreich's ataxia has been slower and more uneven than the pivotal trial population would have predicted. The drivers are infrastructure, payer behaviour, and patient-specialist matching, not the underlying clinical evidence.
JAK class label restrictions are reshaping moderate-disease prescribing
FDA boxed warnings and EMA caution have repositioned JAK inhibitors as later-line agents in rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis - reshaping the practical sequencing decision in moderate disease.
GLP-1 supply is normalising; access still depends on indication
Manufacturing capacity expansion has eased the chronic supply shortfall that defined 2023-24, but reimbursement variation by indication - obesity vs diabetes vs cardiovascular risk reduction - continues to define who can actually start therapy.
Newborn screening expansion is uneven across US states
RUSP additions tell only half the story - state-level implementation timelines stretch the diagnostic-to-treatment gap, and the variation has consequences for treatment-eligibility windows in time-sensitive rare disease.
Severe asthma biologics: which patients are still being left out?
Type-2 biologics have transformed severe eosinophilic asthma management, but a meaningful subset of severe-asthma patients - those without high eosinophils, FeNO, or specific allergic phenotypes - still lack a biomarker-aligned biologic option.
Tau PET reimbursement is the next diagnostic access question
Amyloid PET has settled into routine coverage and availability. Tau PET - which will be the confirmatory pathway for tau-directed therapies - is sited at meaningfully fewer centers and reimbursed unevenly. The access conversation that defined anti-amyloid rollout is about to repeat, one mechanism later.
Real-world ARIA rates from registries are landing close to trial estimates
Early registry data on lecanemab and donanemab in routine clinical use is producing ARIA incidence numbers that broadly track the pivotal trials, with APOE4 homozygotes consistently the highest-risk group.
Plasma-biomarker rollout is concentrated at academic centers
Adoption of plasma p-tau217 testing remains concentrated at academic medical centers and large specialty practices, with community uptake meaningfully behind.
Commercial payer coverage of anti-amyloid therapy is diverging from Medicare
Commercial payers are setting prior authorization and step-therapy criteria that meaningfully diverge from Medicare's coverage-with-evidence-development frame.
Caregiver support is becoming part of the Alzheimer's policy frame
CMS's GUIDE Model and adjacent caregiver-support policy are reshaping how dementia care is paid for outside the medication and diagnostic frame.
NICE keeps the UK out of step with US and EU on anti-amyloid coverage
NICE's negative cost-effectiveness opinion on lecanemab and donanemab leaves the UK as a meaningful policy outlier, even after MHRA authorization.
Lecanemab uptake constrained by infusion infrastructure, not demand
Real-world rollout of lecanemab is gated by infusion-chair capacity and MRI monitoring schedules - not by patient interest or prescriber willingness.
ARIA surveillance is becoming the rate-limiting step in anti-amyloid care
Amyloid-related imaging abnormalities require protocol-defined MRI at multiple intervals, and managing positive findings demands neurologist judgment that is in short supply.
Subcutaneous anti-amyloid formulations move toward filing
Subcutaneous lecanemab data has been submitted to regulators; subcutaneous donanemab is in late development. Both reframe the access question.
Medicare's coverage-with-evidence-development decision still shapes the rollout
The CMS coverage framework requiring registry participation has had measurable effects on which sites prescribe and where patients get treated.
Snapshots
7Tobacco use disorder therapy reference (2026)
Reference snapshot of tobacco use disorder therapy across pharmacotherapy, behavioural support, and integrated care models.
Vasomotor symptom therapy reference (2026)
Reference snapshot of vasomotor symptom therapy across hormone, non-hormonal pharmacotherapy, and emerging mechanism-targeted tiers.
Migraine prevention therapy class reference (2026)
Reference snapshot of approved migraine prevention options including CGRP class, traditional preventives, and emerging mechanisms.
What we are watching in Alzheimer's, as of Q2 2026
A reference list of the threads PatientSpotlight is actively tracking - clinical readouts, regulatory and reimbursement decisions, real-world evidence accumulation, and operational rollout. Each thread names what to watch and why it matters, without predicting when it will resolve.
Caregiver support landscape for Alzheimer's disease, as of Q2 2026
A reference view of the federal, state, employer, and direct-support programs that currently exist for unpaid family caregivers of people with Alzheimer's disease in the US, with notes on the UK and EU.
Payer coverage for anti-amyloid therapy, as of Q2 2026
A reference view of how anti-amyloid therapy is currently covered across US Medicare, Medicare Advantage, US commercial payers, and select international markets.
Alzheimer's regulatory and reimbursement landscape, as of Q2 2026
Two anti-amyloid antibodies have traditional FDA approval; CMS coverage operates under a coverage-with-evidence-development framework; international approvals diverge.
Explained
12What is tobacco use disorder?
Plain-language primer on tobacco use disorder, why quitting is difficult, and what the modern combined approach can offer.
How contraception innovation is being reshaped by the long-acting reversible class
Contraceptive innovation has shifted from oral and short-acting options toward long-acting reversible contraception (LARC) including hormonal IUDs, copper IUDs, and contraceptive implants. The commercial logic, the access frame, and the implications for the broader reproductive health pipeline are worth understanding.
Preeclampsia screening: where biomarker-based pathways are converting
Preeclampsia screening has moved from clinical-risk-factor-driven to biomarker-augmented pathways in several markets. The methodology, the access frame, and the implications for both maternal outcomes and commercial planning around adjacent assets are worth understanding.
ctDNA-guided treatment decisions are entering routine oncology care
Circulating tumour DNA testing has moved from research-grade tool to a routine decision aid in several oncology indications. The pathways from blood draw to clinical decision are now described well enough to plan around, even though reimbursement remains uneven.
How orphan drug designation reshapes commercial planning across markets
Orphan drug designation is more than a marketing-exclusivity tag. It carries fee waivers, accelerated review pathways, market-exclusivity protection, and HTA-layer implications that shape commercial planning materially across markets.
Why 'tumor-agnostic' approvals are reshaping reimbursement reviews
When a drug is approved for a molecular target across tumor types rather than for one cancer, the HTA review framework has to evaluate efficacy across heterogeneous indications with different unmet needs, comparators, and standard-of-care benchmarks. That has practical consequences for access timelines.
How payer step-therapy evolved from a cost tool into a sequencing rulebook
Step-therapy began as a way for payers to manage spend on competing biologics with similar efficacy. It has, over the past decade, become a de-facto sequencing rulebook that defines the order in which classes are tried regardless of which class fits the patient's phenotype best. The clinical and patient-experience consequences are larger than the cost-management origin would suggest.
What is a subcutaneous anti-amyloid antibody, and why does it matter for access?
Subcutaneous formulations of the anti-amyloid antibodies are reformulations that allow the same active drug to be given as a small under-the-skin injection rather than an intravenous infusion. The biology is the same. The delivery is dramatically simpler. The access implications are real but partial - subcutaneous administration removes the infusion-chair constraint, but does not change the MRI surveillance requirement.
What is tau PET, and how is it different from amyloid PET?
Tau PET is a brain scan that shows the build-up of tau, the second protein associated with Alzheimer's disease. The image is closer to the clinical picture than amyloid is - tau accumulation tracks more directly with where and how a person is currently impaired. The trade-off is that tau PET is harder to access than amyloid PET, and the access gap is now a rate-limiter on multiple fronts.
What is Medicare coverage with evidence development?
Coverage with evidence development (CED) is a Medicare coverage mechanism that pays for a treatment on the condition that clinical data about its use is collected and reported back to CMS. It is how Medicare currently covers anti-amyloid antibodies.
What is the CMS GUIDE Model, and who is it for?
The Guiding an Improved Dementia Experience (GUIDE) Model is a Medicare payment pathway for comprehensive dementia care - including direct support for family caregivers. It pays participating practices to deliver a coordinated care package that standard Medicare doesn't.
What is ALZ-NET, and what does it do with patient data?
ALZ-NET is the Alzheimer's Network for Treatment and Diagnostics - the main patient registry collecting real-world data on people receiving anti-amyloid therapy in the US. It is the registry that Medicare's coverage-with-evidence-development framework routes patients through.